PT  - JOURNAL ARTICLE
AU  - Cake, Caroline
AU  - Ogburn, Emma
AU  - Pinches, Heather
AU  - Coleman, Garry
AU  - Seymour, David
AU  - Woodard, Fran
AU  - Manohar, Sinduja
AU  - Monsur, Marjia
AU  - Landray, Martin
AU  - Dalton, Gaynor
AU  - Morris, Andrew D
AU  - Chinnery, Patrick F.
AU  - ,
AU  - Hobbs, FD Richard
AU  - Butler, Christopher
TI  - Development and evaluation of rapid data-enabled access to routine clinical information to enhance early recruitment to the national clinical platform trial of COVID-19 community treatments
AID  - 10.1101/2021.01.15.21249724
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.01.15.21249724
4099  - http://medrxiv.org/content/early/2021/01/15/2021.01.15.21249724.short
4100  - http://medrxiv.org/content/early/2021/01/15/2021.01.15.21249724.full
AB  - Background The COVID-19 pandemic has presented unique challenges for rapidly designing, initiating, and delivering therapeutic clinical trials. PRINCIPLE is the UK national platform investigating repurposed therapies for COVID-19 treatment of older people in the community at high risk of complications. Standard methods of patient recruitment were failing to meet the required pace and scale of enrolment.This paper describes the development and appraisal of a near real-time, data-driven, ethical approach for enhancing recruitment in community care by contacting people with a recent COVID-19 positive test result from the central NHS Test and Trace service within 24-48 hours of their test result.Methods A multi-disciplinary team was formed to solve the technical, ethical, public perception, logistical and information governance issues required to provide a near-real time (within 24-48 hours of receiving a positive test) feed of potential trial participants from test result data to the research team. PRINCIPLE was also given unique access to the Summary Care Record (SCR) to ensure safe prescribing, and to enable the trial team to quickly and safely bring consented patients into the trial. A survey of the public was used to understand public perceptions of the use of test data for this proposed methodology.Results Prior to establishing the data service, PRINCIPLE registered on average 87 participants per week. This increased by up to 87 additional people registered per week from the test data, contributing to an increase from 1,013 recruits to PRINCIPLE at the start of October 2020 to 2,802 recruits by 20th December 2020.While procedural caveats were identified by the public consultation, out of 2,639 people contacted by PRINCIPLE following a positive test result, no one raised a concern about being approached.Conclusions This paper describes a novel approach to using near-real time NHS operational data to recruit community-based patients within a few days of presentation with acute illness.This approach increased recruitment, and reduced time between positive test and randomisation, allowing more rapid evaluation of treatments and increased safety for participants. End-to-end public and patient involvement in the design of the approach provided evidence to inform information governance decisions.Trial registration PRINCIPLE is funded by UK Research and Innovation and the Department of Health and Social Care through the National Institute for Health Research.EudraCT number: 2020-001209-22ISRCTN registry: ISRCTN86534580REC number: 20/SC/058IRAS number: 281958Competing Interest StatementCompeting interests CCB and FDRH are the co-PIs for PRINCIPLE, CC, DS, SM and AM are employees of Health Data Research UK. Clinical TrialISRCTN86534580Funding StatementFunding PRINCIPLE is funded by UKRI Urgent Public Health Priority COVID scheme. FDRH acknowledges part-funding from the National Institute for Health Research (NIHR) School for Primary Care Research, the NIHR Collaboration for Leadership in Health Research and Care (CLARHC) Oxford, the NIHR Oxford Biomedical Research Centre (BRC, UHT), and the NIHR Oxford Medtech and In-Vitro Diagnostics Co-operative (MIC). The National Core Study Data & Connectivity programme is funded by UKRI. Health Data Research UK receives core funding from Medical Research Council (MRC), Engineering and Physical Sciences Research Council, Economic and Social Research Council, Department of Health and Social Care, Health and Care Research Wales, Chief Scientists Office (Scotland), Public Health Agency (Northern Ireland), Wellcome and British Heart Foundation; together known as the Core Funders. NHS DigiTrials receives funding from the Digital Innovation Hubs programme, led by HDR UK. NHS Digital receives funding from the Data & Connectivity National Core Study, this has been used to fund the service delivery described in this paper. MJL receives core funding from HDR UK, NIHR Oxford Biomedical Research Centre, and MRC Population Health Research Unit. PFC is a Wellcome Trust Principal Research Fellow (212219/Z/18/Z), and a UK NIHR Senior Investigator, who receives support from the Medical Research Council Mitochondrial Biology Unit (MC_UU_00015/9), the Medical Research Council (MRC) International Centre for Genomic Medicine in Neuromuscular Disease (MR/S005021/1), the Leverhulme Trust (RPG-2018-408), an MRC research grant (MR/S035699/1), an Alzheimer's Society Project Grant (AS-PG-18b-022) and the National Institute for Health Research (NIHR) Biomedical Research Centre based at Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health and Social Care. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This trial has been ethically reviewed and approved by the South Central Berkshire Research Ethics Committee on the 26th March 2020 (REC reference: 20/SC/0158).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated or analysed during this study are included in this published articleCOPIControl of Patient Information RegulationsCOVID-192019 novel coronavirusDHSCDepartment for Health and Social CareGPGeneral PractitionerHDR UKHealth Data Research UKICOInformation Commissioner’s OfficeLASLondon Ambulance ServiceNCSNational Core StudyNHSNational Health ServiceNHS111 NHS urgent medical help serviceNHSDNHS DigitalPECRPrivacy and Electronic Communications RegulationsPRINCIPLEPlatform Randomised Control Trial of Interventions against COVID-19 in older peopleRCGPRoyal College of General PractitionersRCTRandomised Control TrialRECOVERYRandomised Evaluation of COVID-19 TherapySCRSummary Care Record